Browsing by author "Zalcberg, John"
Sort by:
Title A-Z
-
Developing an Australian Melanoma Clinical Outcomes Registry (MelCOR): a protocol paper
Jobson, Dale; Roffey, Benjamin; Best, Renee; Button-Sloan, Alison; Cossio, Danica; Evans, Sue; Shang, Catherine; Moore, Julie; Arnold, Christopher; Mann, Graham; Shackleton, Mark; Soyer, H Peter; Morton, Rachael L; Zalcberg, John; Mar, VictoriaPublished 2022Introduction Australia has the highest incidence of melanoma in the world with variable care provided by a diverse range of clinicians. Clinical quality registries aim to identify these variations in care and provide ...Open AccessArticle -
Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib
Lee, Chee Khoon; Goldstein, David; Gibbs, Emma; Joensuu, Heikki; Zalcberg, John; Verweij, Jaap; Casali, Paolo G; Maki, Robert G; Cioffi, Angela; McArthur, Grant; Lord, Sarah J; Yip, Desmond; Kanjanapan, Yada; Rutkowski, PiotrPublished 2015-03-19Purpose Metastatic gastrointestinal stromal tumor (GIST) is generally an incurable disease with variable response to imatinib. We aimed to develop prognostic nomograms to predict overall survival (OS) and progression-free ...Open AccessArticle -
Making the move to a learning healthcare system: has the pandemic brought us one step closer?
Symons, Tanya; Zalcberg, John; Morris, JonathanPublished 2021The notion of a learning healthcare system (LHS) is gaining traction to advance the objectives of high-quality patient-centred care. Within such a system, real-world data analysis, clinical research and health service ...Article -
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis
Clarke, Stephen; Yip, Sonia; Brown, Chris; Van Hazel, Guy; Ransom, David T; Goldstein, David; Jeffrey, G Mark; Tebbutt, Niall C; Buck, Martin; Lowenthal, Raymond M; Boland, Amy; Gebski, Val; Zalcberg, John; Simes, R JohnPublished 2011-06-10Background Second-line treatment with irinotecan for advanced or metastatic colorectal cancer prolongs survival. It is uncertain whether irinotecan is better administered with 5- fluorouracil or alone in patients previously ...Open AccessArticle -
Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas
Casali, Paolo; Le Cesne, Axel; Velasco, Andres Poveda; Kotasak, Dusan; Rutkowski, Piotr; Hohenberger, Peter; Fumagalli, Elena; Judson, Ian; Italiano, Antoine; Gelderblom, Hans; Antoine, Adenis; Hartmann, Jorg; Duffaud, Florence; Goldstein, David; Broto, Javier; Gronchi, Alessandro; Dei Tos, Angelo; Marreaud, Sandrine; van der Graff, Winette; Zalcberg, John; Litiere, Saskia; Blay, Jean-YvesPublished 2015-12-01Purpose In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery patients with localized, high- or intermediate-risk GI stromal tumor (GIST). Patients and Methods ...Open AccessArticle
Sort by:
Title A-Z